Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Technical AnalystHold
Rating4/10
Generated at:2026-03-04 16:37:07
Analysis based on Moderna, Inc. (MRNA) US stock market data from 2025-12-05 to 2026-03-04, covering 90 calendar days and 60 trading days, pricing in US dollars, data completeness confirmed for technical analysis
Insight

MRNA shows strong bullish momentum but is significantly overbought with multiple indicators suggesting limited near-term upside potential.

Resistance
59.55
Support
0.00
Support and resistance are estimated from the latest 60 sessions.
Strategy
  • Short-term:For existing holders: maintain positions with trailing stop-loss at $51.69, consider partial profits. For new positions: wait for pullback to $49-52 support zone, avoid chasing current momentum.
  • Mid-term:Monitor for break below 20-day MA ($46.97) as potential trend change signal, maintain conservative position sizing given high volatility.
  • Long-term:Consider re-entry on significant pullbacks to support levels, focus on risk management due to biotech volatility and historical tendency for sharp reversals.

Moving averages

MA 5
53.15
MA 20
46.97
MA 60
39.91
Price
57.80
AI Analysis
  • Moving average structure shows clear bullish alignment
  • MA_5: $53.15, MA_10: $51.75, MA_20: $46.97, MA_60: $39.91
  • Current price of $57.80 is trading significantly above all major moving averages
  • Configuration (5-day > 10-day > 20-day > 60-day) represents classic bullish moving average stack
  • Indicates sustained positive momentum
  • 60-day moving average at $39.91 provides strong long-term support level approximately 31% below current price

Volume

Volume
22.30M
20D Avg
10.11M
Institution
-
Participation
-
AI Analysis
  • Trading volume has been highly variable with several notable spikes
  • January 22: 34.1M shares (peak volume)
  • March 4: 22.3M shares (recent surge)
  • December 19: 23.5M shares (initial breakout)
  • Volume pattern shows characteristic biotech stock behavior
  • Low volume during consolidation periods and explosive volume during breakout moves
  • Recent high volume on March 4th suggests institutional participation in latest move higher

MACD

MACD
3.52
Signal
2.92
Hist
0.60
Trend
-
AI Analysis
  • MACD indicators show continued bullish momentum
  • MACD: 3.5187, MACD Signal: 2.9185, MACD Histogram: 0.6002
  • MACD line remains above its signal line with positive histogram reading
  • Indicates ongoing bullish momentum
  • Represents continuation of positive trend that began in late December 2025
  • Magnitude of MACD reading suggests momentum may be approaching extended levels

Bollinger bands

Upper
57.69
Middle
46.97
Lower
36.25
Width
45.64%
AI Analysis
  • Bollinger Band positioning indicates strong momentum
  • Upper Band: $57.69, Middle Band: $46.97, Lower Band: $36.25
  • Current Price: $57.80 trading at upper Bollinger Band
  • Typically suggests strong momentum but also potential overextension
  • Band width (upper-lower = $21.44) indicates high volatility characteristic of MRNA's trading pattern
  • Trading at upper band often signals potential for continuation or near-term consolidation

RSI

RSI(14)
72.57
RSI(6)
77.14
Overbought
70+
Oversold
30-
AI Analysis
  • RSI indicators show overbought conditions
  • RSI (14-period): 72.57, RSI (6-period): 77.14
  • Both RSI readings significantly above traditional overbought threshold of 70
  • Indicates stock is in overbought territory
  • 6-period RSI at 77.14 is particularly elevated
  • Suggests short-term buying pressure may be excessive
  • Historically, RSI levels above 70 have often preceded consolidation or pullbacks in MRNA

KDJ

K
75.59
D
79.06
J
68.64
Trend
-
AI Analysis
  • KDJ oscillator shows mixed signals
  • K: 75.59, D: 79.06, J: 68.64
  • With K and D values above 75, stock is in overbought territory
  • J value at 68.64 is relatively lower
  • Suggests some divergence that may indicate potential for near-term consolidation rather than immediate reversal

Chip distribution

How chip distribution helps you?
Chip distribution summary
  • Nearly all holders are profitable with moderate concentration, creating potential selling pressure if weakness emerges.
  • Profit Ratio: 97.48% - Nearly all holders are in profit
  • Average Cost: $51.25 - Just below current price levels
  • 90% Cost Range: $42.65-$57.09 - Majority of holders acquired between these levels
  • 90% Concentration: 14.48% - Moderate concentration within this range
  • Distribution suggests most market participants are currently profitable
  • Could create selling pressure if stock shows signs of weakness
  • Concentration metrics indicate relatively dispersed holdings rather than concentrated positions
No chart data

Data is estimated based on turnover rate, high, low, open, and close prices. Profit ratios may vary significantly across different brokerage tools.